The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 20, 2025

Filed:

Aug. 09, 2019
Applicant:

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

Inventors:

Tomoyuki Igawa, Singapore, SG;

Mika Sakurai, Shizuoka, JP;

Shun Shimizu, Shizuoka, JP;

Yuji Hori, Shizuoka, JP;

Naoka Hironiwa, Singapore, SG;

Nasa Savory, Shizuoka, JP;

Yoshinori Narita, Kanagawa, JP;

Takayuki Kamikawa, Kanagawa, JP;

Taro Miyazaki, Tokyo, JP;

Shojiro Kadono, Shizuoka, JP;

Masami Hasegawa, Kanagawa, JP;

Kanako Tatsumi, Shizuoka, JP;

Akira Hayasaka, Shizuoka, JP;

Takeaki Kawai, Shizuoka, JP;

Futa Mimoto, Singapore, SG;

Hiroki Kawauchi, Kanagawa, JP;

Masaki Kamimura, Kanagawa, JP;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 47/6849 (2017.08); A61K 2039/505 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01);
Abstract

An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same. Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided. The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.


Find Patent Forward Citations

Loading…